Cancer combo trial halted early: what happened?
Disease control
Terminated
This study tested a combination of two drugs (donafenib and KN046) in 15 people with advanced gastrointestinal cancers that had not responded to standard treatments. The goal was to see if the combination was safe and could shrink tumors. The trial was terminated early, so result…
Phase: PHASE1, PHASE2 • Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd • Aim: Disease control
Last updated May 14, 2026 12:03 UTC